Understand the source comparison
Epithalon Longevity Complete Guide 2026: Comparison Table
Epithalon Activates telomerase (TERT), lengthens telomeres, restores pineal melatonin 12-year observational study (N=266): 28% mortality reduction; Phase II trial: 42% telomere lengthening 10 mg daily × 10–20 days, 1–2 cycles/year Direct lengthening (30–40% in
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Epithalon
- Activates telomerase (TERT), lengthens telomeres, restores pineal melatonin
- 12-year observational study (N=266): 28% mortality reduction; Phase II trial: 42% telomere lengthening
- 10 mg daily × 10–20 days, 1–2 cycles/year
- Direct lengthening (30–40% increase in human lymphocytes)
- Strongest telomere data, limited to Russian trials, no independent Western replication
- TA-65 (Astragalus extract)
- Weak telomerase activation via cycloastragenol
- Observational cohort (N=97): modest telomere maintenance, no mortality data
- 250–1000 mg daily, continuous
- Stabilisation only. Prevents shortening but doesn't lengthen
- Expensive, minimal effect size, weaker mechanism than epithalon
- Senolytics (Dasatinib + Quercetin)
- Clears senescent cells (non-dividing cells that secrete inflammatory factors)
- Phase I safety trials only; no longevity endpoints
- Intermittent (3 days/month)
- No direct telomere effect
- Promising for healthspan, unproven for lifespan extension
- NAD+ precursors (NMN, NR)
- Restores NAD+ levels, activates sirtuins (SIRT1, SIRT6)
- Phase II metabolic trials; no mortality data
- Indirect. Sirtuins may influence telomere maintenance
- Metabolic benefits clear, longevity claims speculative
- Metformin
- AMPK activation, mTOR inhibition, insulin sensitisation
- TAME trial (ongoing): targeting 3,000 elderly patients for mortality outcomes
- 500–1500 mg daily, continuous
- Best evidence base for lifespan extension in humans, mechanisms differ from epithalon